CAM
REGN icon

Cresset Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cresset Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,700
Closed -$1.57M – 1968
2023
Q4 		$1.57M Sell
2,700
-24,800
-90% -$20.4M 0.01% 689
2023
Q3 		$22.6M Sell
27,500
-222,500
-89% -$175M 0.09% 117
2023
Q2 		$180M Buy
+250,000
New +$193M 0.22% 32

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cresset Asset Management's REGN Position: Q1 2026 in Review

Cresset Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, selling an estimated $243K and leaving 2,537 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #562.

Cresset Asset Management first reported a position in REGN in Q4 2018 and has held it in 28 quarters since. The position peaked at $11M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Cresset Asset Management held 2,537 shares of Regeneron Pharmaceuticals worth $1.96M as of Q1 2026.
  • Cresset Asset Management sold 318 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $243K.
  • Regeneron Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q1 2026, its #562 holding.
  • Cresset Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Cresset Asset Management's Regeneron Pharmaceuticals position peaked at $11M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.